The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Open accessThe DOI matches its Crossref record; 446 of the 448 references it cites were found in a registry or an index.
Abstract
Therapeutic approaches that lower circulating low-density lipoprotein (LDL)-cholesterol significantly reduced the burden of cardiovascular disease over the last decades. However, the persistent rise in the obesity epidemic is beginning to reverse this decline. Alongside obesity, the incidence of nonalcoholic fatty liver disease (NAFLD) has substantially increased in the last three decades. Currently, approximately one third of world population is affected by NAFLD. Notably, the presence of NAFLD and particularly its more severe form, nonalcoholic steatohepatitis (NASH), serves as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), thus, raising interest in the relationship between these two diseases. Importantly, ASCVD is the major cause of death in patients with NASH independent of traditional risk factors. Nevertheless, the pathophysiology linking NAFLD/NASH with ASCVD remains poorly understood. While dyslipidemia is a common risk factor underlying both diseases, therapies that lower circulating LDL-cholesterol are largely ineffective against NASH. While there are no approved pharmacological therapies for NASH, some of the most advanced drug candidates exacerbate atherogenic dyslipidemia, raising concerns regarding their adverse cardiovascular consequences. In this review, we address current gaps in our understanding of the mechanisms linking NAFLD/NASH and ASCVD, explore strategies to simultaneously model these diseases, evaluate emerging biomarkers that may be useful to diagnose the presence of both diseases, and discuss investigational approaches and ongoing clinical trials that potentially target both diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“fibrotic MASH is an independent risk factor for atherosclerotic cardiovascular disease, which is the leading cause of death in people with MASH (56).”
From Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis (2025) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · cited 4×
“Excluding CVD, liver fibrosis is the major cause of liver-related mortality in patients with NASH (47, 50).”
BackgroundInfluentialAMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Research works printed but not linked: 2
- Linton MRF Yancey PG Davies SS Jerome WG Linton EF Song WL The role of lipids and lipoproteins in atherosclerosis. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. Endotext. South Dartmouth (MA, U.S.A.) (2000). p. 1– 144.
- Ignatowski A. Influence of animal food on the organsim of rabbits. Izvest Imper Voennomed Akad St Petersburg. (1908) 16: 154– 73.
Cited by
Zheng, H., Sechi, L. A., Navarese, E. P., Casu, G., & Vidili, G. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02434-5 · Cited by 185
“Elevated TG levels are associated with an increased risk of CVD, as they can directly and indirectly contribute to atherosclerosis by forming sdLDL particles that are particularly atherogenic [83].”
BackgroundAmino Acid Metabolism and Atherosclerotic Cardiovascular Disease
Anand, S. K., Governale, T.-A., Zhang, X., Razani, B., Yurdagul, A., Pattillo, C. B., & Rom, O. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.12.006 · Cited by 55
Self-citationWhat are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
Tarantino, G., & Citro, V. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02031-1 · Cited by 40
“There are conflicting results related to the role of SIRT4 in the development of atherosclerosis, which is strongly associated with NAFLD [144] and heavy alcohol consumption [145].”
BackgroundMetabolomics at the cutting edge of risk prediction of MASLD
Tan, E. Y., Muthiah, M. D., & Sanyal, A. J. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101853 · Cited by 50
“5,54 Interestingly, certain genetic polymorphisms such as in PNPLA3 and TM6SF2 favor MASLD development but are associated with a lower-risk lipoprotein profile 55 ; these are discussed later in this review.”
Shi, H., Wang, X., Sloas, C., Gerlach, B., Yurdagul, A., Moore, M. P., Jung, E. J., Mirshahi, F., Ronzoni, L., Sanyal, A. J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv2106 · Cited by 30
Self-citationEHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
Ma, F., Longo, M., Meroni, M., Bhattacharya, D., Paolini, E., Mughal, S., Hussain, S., Anand, S. K., Gupta, N., Zhu, Y., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.020 · Cited by 29
Self-citationDas, S. R., Finney, A. C., Anand, S. K., Rohilla, S., Liu, Y., Pandey, N. O., Ghrayeb, A., Kumar, D., Núñez, K., Liu, Z., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01134-4 · Cited by 31
“Given that the predominant cause of mortality in patients with MASH is complications due to cardiovascular disease 64 , identifying pathways that can be targeted for simultaneous treatment of MASH and cardiovascular disease is challenging and urgently needed.”
Self-citationRole of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines
Pezzino, S., Luca, T., Castorina, M., Puleo, S., Latteri, S., & Castorina, S. (2024) · Life · doi:10.3390/life14010093 · Cited by 31
“Increased rates of clinically significant thrombotic events, such as pulmonary embolism, deep vein thrombosis, and portal vein thrombosis, are explicable by abnormalities at all stages of hemostasis [83,84], including a condition of hypercoagulation derived from decreased levels of PAI-1 [61,72,73].”
BackgroundGallo, G., Nalli, G., Baratta, F., Desideri, G., & Savoia, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168081 · Cited by 27
“Excess caloric intake is also converted into triglycerides, which stimulate the production of small dense LDL (sdLDL) particles and contribute to arterial wall thickening, thereby elevating cardiovascular risk [172].”
Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping
Habib, S. (2024) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v15.i2.92791 · Cited by 24
“Also, similar to TM6SF2 mutation, PNPLA3 rs738409 G allele is associated with a low risk of cardiovascular events, owing to the tight association with lower serum LDL level, as low LDL-C and high HDL-C are cardioprotective[50,59].”
Mechanisms Behind NAFLD: a System Genetics Perspective
Pourteymour, S., Drevon, C. A., Dalen, K. T., & Norheim, F. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01158-3 · Cited by 16
Biomarkers of Hepatic Dysfunction and Cardiovascular Risk
Lee, T. B., Kueh, M. T. W., Jain, V., Razavi, A. C., Alebna, P. L., Chew, N., & Mehta, A. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01993-5 · Cited by 16
Boullion, J. A., Husein, A., Agrawal, A., Xing, D., Hossain, M. I., Bhuiyan, M. S., Rom, O., Conrad, S. A., Vanchiere, J. A., Orr, A. W., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf111 · Cited by 14
Self-citationGarcía, S. G., Martínez‐Domínguez, S. J., Gargallo-Puyuelo, C. J., Gallego, B., Alfambra, E., Gonzalvo, M. C. A., Martínez-Micaelo, N., Amigó, N., Martínez-García, J., Baptista, P. M., et al. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2023.11.032 · Cited by 6
Nidogen 2 Overexpression Promotes Hepatosteatosis and Atherosclerosis
Kathuria, I., Prasad, A., Sharma, B. K., Ofosu‐Boateng, M., Aithabathula, R. V., Gyamfi, M. A., Jiang, J., Park, F., Singh, U. P., & Singla, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312782 · Cited by 6
“Notably, ASCVD is recognized as the major cause of death among NAFLD patients, independent of traditional risk factors [8].”
Mishra, B. H., Raitoharju, E., Mononen, N., Saarinen, A. I. L., Viikari, J. S. A., Juonala, M., Hutri‐Kähönen, N., Kähönen, M. A. P., Raitakari, O. T., Lehtimäki, T. J., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1345159 · Cited by 5
“NAFLD is an independent risk factor for atherosclerotic CVD (48).”
Das, S. R., Anand, S. K., McKinney, M. P., Richard, K. S. E., Mahmud, I., Rohilla, S., Arias, F., Ghrayeb, A., Wei, B., Tan, L., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101703 · Cited by 7
Self-citationRichard, K. S. E., Rohilla, S., Gade, R., Arias, F., & Rom, O. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01425-z · Cited by 4
“Systemic inflamma - tory markers elevated in MASLD, including CCL2, CCL5, C-reactive protein and IL-6 [6, 7, 29], show strong associations with endothelial dysfunction and subclinical atherosclerosis, supporting the concept that hepatic inflammation amplifies vascular risk.”
InfluentialSelf-citationLiver fibrosis is associated with clinical and economic burden of cardiovascular disease in MASH
Corey, K. E., Mehta, A., Mangla, K. K., Chandramouli, A. S., Shoeb, A., Krarup, N., Augusto, M., Grau, K., Varma, S., & Bugianesi, E. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101621 · Cited by 2
“7,14 While broad CV risk and CV-related mortality has been reported, 16,27,28 there has been less focus on specific CV events and their relative contribution to the clinical and economic burden of MASH.”
Linking MASLD to ACVD through Kupffer cells
Ma, F., Huang, X., & Cai, B. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00442-y · Cited by 2
Self-citationKarády, J., Mayrhofer, T., Foldyna, B., Lu, M. T., Meyersohn, N. M., Hoffmann, U., Balogon, O., Pagidipati, N. J., Shah, S. H., Douglas, P. S., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18415 · Cited by 2
Statin therapy for NAFLD: Molecular underpinnings of myopathic consequences and treatment strategies
Nanepag, P. V., Mangrulkar, S. V., Shriwas, A., Kale, M. B., Kushwaha, S., Wankhede, N. L., Taksande, B. G., & Umekar, M. J. (2025) · Aspects of Molecular Medicine · doi:10.1016/j.amolm.2025.100091 · Cited by 2
R-spondin 2 suppresses hepatic steatosis via activation of AMPK-ACC signaling
Aithabathula, R. V., Singla, B., Kathuria, I., Pervaiz, N., Sharma, B. K., Samake, T. I., Ofosu-Boateng, M., Gebreyesus, L. H., Gyamfi, M. A., Sprague, C., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101551 · Cited by 4
Gutiérrez‐Cuevas, J., Sandoval-Rodriguez, A. S., Garcia-Bañuelos, J. J., Petri, M. H., & Armendáriz‐Borunda, J. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.119898 · Cited by 3
The Clinical Implication of Pemafibrate, a Novel Selective PPARα Modulator
Fujioka, Y. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed275 · Cited by 2
“Patients who use fibrates to prevent ASCVD may be subjects with MASLD/MASH.”
InfluentialYap, Y. W., Rusu, P. M., Foollee, A., & Rose, A. J. (2023) · The Journal of Physiology · doi:10.1113/jp281185 · Cited by 1
Cholesterol-associated Locus EHBP1 Protects against NASH FibrosisPreprint
Ma, F., Longo, M., Huang, X., Meroni, M., Prakash, S., Paolini, E., Bhattacharya, D., Wang, S., Wang, X., Mughal, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.08.548218 · Cited by 1
“Nonetheless, human relevance is supported by the following: (1) the loss-of-function EHBP1 rs10496099 T>C variant is associated with augmented NASH in humans, which is consistent with EHBP1-silenced NASH mice; (2) the protein levels of EHBP1 and sortilin in hepatocytes are decreased in human NASH livers; (3) Sortilin…”
BackgroundSelf-citationDynamic Hepatocholescintigraphy with Bromesida® 99mTc
Петрович, М. С., & Борисович, С. В. (2024) · Journal of radiology and nuclear medicine · doi:10.20862/0042-4676-2023-104-4-279-286
García, S. G., Martínez‐Domínguez, S. J., Gargallo-Puyuelo, C. J., Gallego, B., Alfambra, E., Gonzalvo, M. C. A., Martínez-Micaelo, N., Amigó, N., Martínez-García, J., Baptista, P. M., et al. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2023.11.026
Han, D. G., He, C., Gu, S., Zhang, D., & Xu, L. (2024) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.40.10.10578
“17 the persistent rise in the obesity epidemic is beginning to reverse this decline.”
BackgroundLiver immunology: Biological role and clinical significance
Kotlyarov, S. N. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107541 · Cited by 6
Neifert, A. R., Su, D. G., & Sumpio, B. E. (2025) · Journal of Vascular Diseases · doi:10.3390/jvd4030031 · Cited by 3
Huang, J.-W., Man, N., Wang, H., Ai, X., Wei, D.-L., & Dai, Y. (2025) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s562237
“Cluster D (Oxidative stress) 28–31 mainly explains how oxidative stress, resulting from an imbalance between reactive oxygen species production and antioxidant defense systems, contributed to hepatic cell damage, inflammatory response, and steatosis in MASLD, and its interaction with other…”
Wang, Y., Ding, K., Sun, B., Xu, Q., Zheng, W., Liu, L., Wang, J., Liu, K., Zhang, J., & Zhang, W. (2026) · Database · doi:10.1093/database/baag013 · Cited by 1
Calixto-Tlacomulco, S., Luna-Reyes, I., Villa-Jaimes, G. S., Montalvan‐Sorrosa, D., Gutiérrez‐Vidal, R., Pérez-Hernández, E. G., Picones, A., Durán-Pastén, M. L., Lara-Figueroa, C. O., Hernandez‐Cruz, A., et al. (2026) · Archives of Medical Research · doi:10.1016/j.arcmed.2026.103429
Feng, J., Jin, Y., Zhang, Y., Mei, Y., Pan, Y., Shen, Q., Zeng, C., Cui, Y., & Huangfu, N. (2026) · npj Science of Food · doi:10.1038/s41538-026-00920-6
“…injury, locally in fi l-trated immune cells such as macrophages and neutrophils are continuously activated and release various pro-in fl ammatory factors, which can lead to increased systemic in fl ammatory load and metabolic pressure, aggravatefat deposition and hepatic in fl ammation 19,20 .”
Assessment of metabolic biomarkers associated with hepatic steatosis in Crohn’s disease
Ferrer, C. S., Abadía, M., Sanchez, M. G. C., García, J. L. R., Olveira, A., Romero, M., Molero-Luís, M., Martín-Arranz, E., Azofra, M. S., García, A., et al. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.121707
Dhaou, C. B., Rom, O., & Orr, A. W. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101624
Self-citationPirfenidone restores metabolic hormones and cardiac autophagy via p-AMPK in MASH
López-Cifuentes, D., Sandoval-Rodriguez, A. S., Escutia-Gutiérrez, R., Armendáriz‐Borunda, J., & Gutiérrez‐Cuevas, J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08828-1
Calpain-1 deficiency alleviates oxidative stress and hepatic injury in ApoE-deficient mice with MASH
Gu, W., Wei, Y., Li, S., Awad, M. A., Shi, Y., Jiang, Y., Zhou, X., Wang, Z., 刘继新, & Tang, F. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.104024
Metadata
- Authors
- Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O.
- Affiliations
- Louisiana State University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Yurdagul, Arif
- Rom, Oren
- ORCID
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2023-05-02
- Volume
- 10
- Pages
- 1116861-1116861
- ISSN
- 2297-055X (ISSN-L)
- PMC
- PMC10185914
- OpenAlex
- W4367678781
- Cited by
- 40
- References
- 448
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 16 · 2023: 4
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cardiovascular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (DK134011, HL150233, HL145131, DK115778, GM147269)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, atherosclerotic cardiovascular disease, dyslipidemia, LDL cholesterol lowering, obesity, disease pathophysiology, atherogenic dyslipidemia, biomarkers, disease modeling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.